Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Spermine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 4/20 | 0.93 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.63 |
| ▸ | UBE2N | P61088 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.93 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.93 |
| ▸ | CA12 | O43570 | 5/20 | 0.93 |
| ▸ | CA6 | P23280 | 5/20 | 0.93 |
| ▸ | CA7 | P43166 | 5/20 | 0.93 |
| ▸ | CA9 | Q16790 | 5/20 | 0.93 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.93 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.93 |
| ▸ | CA4 | P22748 | 4/20 | 0.93 |
| ▸ | CA5A | P35218 | 4/20 | 0.93 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.93 |
| ▸ | F13A1 | P00488 | 2/20 | 0.93 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.93 |
| ▸ | THPO | P40225 | 2/20 | 0.93 |
| ▸ | CASP2 | P42575 | 2/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Spermine SCHEMBL7709508 | 1.00 | UBE2N (1.00) | UBE2NMAPTPMP22LMNASMN1; SMN2 | |
| Spermine SCHEMBL348194 | 1.00 | UBE2N (1.00) | UBE2NMAPTPMP22LMNASMN1; SMN2 | |
| Spermine SCHEMBL348192 | 1.00 | UBE2N (1.00) | UBE2NMAPTPMP22LMNASMN1; SMN2 | |
| Spermine SCHEMBL15300022 | 1.00 | UBE2N (1.00) | UBE2NMAPTPMP22LMNASMN1; SMN2 | |
| Spermidine SCHEMBL343877 | 0.97 | LMNA (1.00) | UBE2NMAPTPMP22LMNASMN1; SMN2 | |
| Spermidine SCHEMBL573341 | 0.97 | LMNA (1.00) | UBE2NMAPTPMP22LMNASMN1; SMN2 | |
| Spermidine SCHEMBL573651 | 0.97 | LMNA (1.00) | UBE2NMAPTPMP22LMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL8021183 | 0.97 | UBE2N (0.93) | UBE2NMAPTPMP22LMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL8405003 | 0.97 | UBE2N (0.93) | UBE2NMAPTPMP22LMNASMN1; SMN2 | |
| Spermine SCHEMBL30354062 | 0.97 | UBE2N (0.93) | UBE2NMAPTPMP22LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 365 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115724744-B | Preparation method of spermine hydrochloride | 吉林敖东药业集团延吉股份有限公司 | 2024-07-30 | — | — | CN | claimed |
| CN-114184593-B | Dynamic surface enhanced Raman spectrum detection method | 厦门大学 | 2024-06-04 | — | — | CN | claimed |
| CN-114517181-B | Serum-free medium for human T lymphocyte, and preparation method and application thereof | 大连博格林生物科技有限公司 | 2023-11-24 | — | — | CN | claimed |
| US-20230219881-A1 | Synthesis of Spermidine, Spermine, and Free Bases Thereof | Compound Solutions Inc. (US) | 2023-07-13 | — | — | US | claimed |
| CN-114557337-B | Protein-free non-program freezing solution of umbilical cord mesenchymal stem cells and preparation method thereof | 大连博格林生物科技有限公司 | 2023-05-23 | — | — | CN | claimed |
| CN-115724744-A | Preparation method of spermine hydrochloride | 吉林敖东药业集团延吉股份有限公司 | 2023-03-03 | — | — | CN | claimed |
| CN-114557337-A | Protein-free non-programmed cryopreservation liquid for umbilical cord mesenchymal stem cells and preparation method thereof | 大连博格林生物科技有限公司 | 2022-05-31 | — | — | CN | claimed |
| CN-114517181-A | Serum-free culture medium for human T lymphocytes and preparation method and application thereof | 大连博格林生物科技有限公司 | 2022-05-20 | — | — | CN | claimed |
| CN-114286671-A | Compositions and methods for biological delivery vehicles | DNALite治疗学公司 | 2022-04-05 | — | — | CN | claimed |
| CN-114160805-A | Preparation method and application of electropositive silver nanoparticles | 厦门大学 | 2022-03-11 | — | — | CN | claimed |
| WO-2004096998-A2 | NANOPARTICULAR TUMOR TARGETING AND THERAPY | VANDERBILT UNIVERSITY (US) | 2004-11-11 | — | — | WO | claimed |
| CN-1173045-C | High-yield fermentation method for producing boanmycin | 中国医学科学院医药生物技术研究所 | 2004-10-27 | — | — | CN | claimed |
| US-20040136961-A1 | Nanoparticulate composition for efficient gene transfer | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-07-15 | — | — | US | claimed |
| EP-0873752-B1 | Aqueous solvent based encapsulation of a bovine herpes virus type-1 subunit vaccine | PFIZER (US) | 2004-03-24 | — | — | EP | claimed |
| US-6589563-B2 | Drug delivery system exhibiting permeability control | NANODELIVERY, INC. | 2003-07-08 | — | — | US | claimed |
| US-6383478-B1 | DRUG DELIVERY | VANDERBILT UNIVERSITY | 2002-05-07 | — | — | US | claimed |
| US-6270800-B1 | SALT MEMBRANE COMPRISING A PRECIPITATE RESULTING FROM THE INTERFACIAL REACTION OF SPERMINE AND ALGINIC ACID OR THE INTERFACIAL REACTION OF A WATER-SOLUBLE NEUTRAL SALT OF SPERMINE AND A WATER-SOLUBLE NEUTRAL SALT OF ALGINIC ACID | PFIZER INC. | 2001-08-07 | — | — | US | claimed |
| CN-1303949-A | High-yield fermentation method for producing boanmycin | MEDICAL BIOLOG TECHNOLOGY I CH (CN) | 2001-07-18 | — | — | CN | claimed |
| WO-2000064954-A1 | POLYMERIC ENCAPSULATION SYSTEM PROMOTING ANGIOGENESIS | VANDERBILT UNIVERSITY (US) | 2000-11-02 | — | — | WO | claimed |
| EP-0873752-A2 | Aqueous solvent based encapsulation of a bovine herpes virus type-1 subunit vaccine | PFIZER INC. (US) | 1998-10-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219881-A1 | Synthesis of Spermidine, Spermine, and Free Bases Thereof | SRM, SMS, SMOX | CA2 2235/4885ESR1 4515/4885UBE2N 4266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.